Rixathon 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0071 
Minor change in labelling or package leaflet not 
20/12/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0070 
B.I.b.2.z - Change in test procedure for AS or 
15/12/2023 
n/a 
starting material/reagent/intermediate - Other 
variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
WS/2536 
This was an application for a variation following a 
09/11/2023 
SmPC 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IB/0068 
B.I.a.2.z - Changes in the manufacturing process of 
25/09/2023 
n/a 
the AS - Other variation 
IG/1665/G 
This was an application for a group of variations. 
14/09/2023 
Annex II 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
Page 2/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
22/06/2023 
23/08/2023 
Refer to Scientific conclusions and grounds recommending 
202211 
rituximab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2652/202211. 
WS/2505/G 
This was an application for a group of variations 
13/07/2023 
SmPC 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0065 
B.II.b.3.a - Change in the manufacturing process of 
15/03/2023 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 3/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/2307 
This was an application for a variation following a 
26/01/2023 
24/02/2023 
SmPC 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
WS/2387 
This was an application for a variation following a 
09/02/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
23/06/2022 
17/08/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202111 
rituximab 
the variation to terms of the Marketing Authorisation(s) for 
PSUSA/2652/202111. 
IB/0061 
B.I.a.1.k - Change in the manufacturer of AS or of a 
21/07/2022 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
WS/2271/G 
This was an application for a group of variations 
21/07/2022 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
Page 4/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0060 
B.II.b.5.z - Change to in-process tests or limits 
16/06/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IG/1519 
A.7 - Administrative change - Deletion of 
31/05/2022 
17/08/2022 
Annex II 
manufacturing sites 
WS/2273 
This was an application for a variation following a 
19/05/2022 
17/08/2022 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0057 
B.I.a.4.z - Change to in-process tests or limits 
10/05/2022 
n/a 
applied during the manufacture of the AS - Other 
variation 
Page 5/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R/0053 
Renewal of the marketing authorisation. 
16/12/2021 
24/02/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Rixathon in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
WS/2135/G 
This was an application for a group of variations 
28/10/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.e - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of an in-process test which may have a significant 
effect on the overall quality of the AS 
IB/0051 
C.I.11.z - Introduction of, or change(s) to, the 
20/08/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
24/06/2021 
20/08/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202011 
rituximab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2652/202011. 
IB/0050 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/08/2021 
24/02/2022 
SmPC, 
To update section 6.6 of the SmPC to add new instructions 
generic/hybrid/biosimilar products following 
Labelling and 
on the injections, in line with the reference product. 
Page 6/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PL 
WS/2061/G 
This was an application for a group of variations 
03/06/2021 
20/08/2021 
SmPC, Annex 
The product information was updated as follows: 
II, Labelling 
update of sections 6.3 and 6.4 of the Summary of Product 
and PL 
Characteristics,  
update of section 9 of the labelling,  
update of sections 2, 4 and 5 of the Package Leaflet 
In addition editorial corrections were introduced and 
addition in Annex II ‘The printed package leaflet of the 
medicinal product must state the name and address of the 
manufacturer responsible for the release of the concerned 
batch.’ 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IB/0049 
B.II.b.4.a - Change in the batch size (including batch 
12/05/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
WS/1996 
This was an application for a variation following a 
04/02/2021 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
Page 7/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0045 
B.II.c.2.d - Change in test procedure for an excipient 
09/12/2020 
n/a 
- Other changes to a test procedure (including 
replacement or addition) 
IB/0044 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
24/11/2020 
n/a 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
WS/1875/G 
This was an application for a group of variations 
03/09/2020 
09/10/2020 
SmPC, 
Labelling and 
PL 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 8/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
IB/0043 
B.I.e.5.c - Implementation of changes foreseen in an 
31/08/2020 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0041 
C.I.11.z - Introduction of, or change(s) to, the 
23/08/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0038 
B.I.e.5.c - Implementation of changes foreseen in an 
11/06/2020 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
201911 
rituximab 
IB/0040 
B.I.a.1.z - Change in the manufacturer of AS or of a 
04/06/2020 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0039 
B.I.a.2.a - Changes in the manufacturing process of 
03/06/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IG/1212 
A.4 - Administrative change - Change in the name 
20/02/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 9/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0033 
B.II.b.4.z - Change in the batch size (including batch 
08/01/2020 
n/a 
size ranges) of the finished product - Other variation 
IB/0032 
B.II.g.5.c - Implementation of changes foreseen in 
16/12/2019 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
IB/0031 
B.II.g.4.b - Changes to an approved change 
08/11/2019 
n/a 
management protocol - Minor changes that do not 
change the strategy defined in the protocol 
WS/1678 
This was an application for a variation following a 
07/11/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
IB/0030 
B.II.b.5.z - Change to in-process tests or limits 
24/09/2019 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0029 
B.I.a.4.z - Change to in-process tests or limits 
10/09/2019 
n/a 
applied during the manufacture of the AS - Other 
variation 
WS/1599 
This was an application for a variation following a 
05/09/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.13 - Other variations not specifically covered 
Page 10/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0026/G 
This was an application for a group of variations. 
29/08/2019 
23/09/2019 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0028 
B.I.e.5.c - Implementation of changes foreseen in an 
09/08/2019 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0025/G 
This was an application for a group of variations. 
19/07/2019 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
Page 11/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
WS/1642/G 
This was an application for a group of variations 
18/07/2019 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
201811 
rituximab 
IB/0022 
B.I.e.5.c - Implementation of changes foreseen in an 
30/05/2019 
23/09/2019 
Annex II 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0023 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
14/05/2019 
23/09/2019 
SmPC 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
IG/1084/G 
This was an application for a group of variations. 
05/04/2019 
n/a 
Page 12/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IAIN/0018 
B.II.b.2.c.1 - Change to importer, batch release 
25/02/2019 
23/09/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
WS/1528 
This was an application for a variation following a 
31/01/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
WS/1480 
This was an application for a variation following a 
17/01/2019 
n/a 
worksharing procedure according to Article 20 of 
Page 13/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commission Regulation (EC) No 1234/2008. 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
WS/1462 
This was an application for a variation following a 
06/12/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
IB/0016 
B.II.c.1.b - Change in the specification parameters 
22/10/2018 
n/a 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
WS/1452 
This was an application for a variation following a 
13/09/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.d.2.z - Change in test procedure for the finished 
product - Other variation 
WS/1335 
This was an application for a variation following a 
12/07/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Submission of final study reports for studies GP13-
302 (a randomized, double-blind, parallel-group 
safety study with the aim to specifically address a 
Page 14/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
potential safety risk of a switch from treatment with 
originator rituximab (Mabthera/Rituxan) to treatment 
with GP2013) and GP13-201 (a 52-week multicenter, 
randomized, double-blind, parallel-arm, comparative 
study in patients with active Reumathoid Arthritis 
(RA) refractory or intolerant to standard DMARDs 
and one or up to three anti-TNFs therapies). The 
RMP (version 3.1) has been updated accordingly. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IG/0939/G 
This was an application for a group of variations. 
15/06/2018 
n/a 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
201711 
rituximab 
IB/0011 
B.II.g.5.c - Implementation of changes foreseen in 
23/04/2018 
n/a 
an approved change management protocol - For a 
Page 15/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological/immunological medicinal product 
IG/0878/G 
This was an application for a group of variations. 
11/12/2017 
n/a 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
IB/0007 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
14/11/2017 
n/a 
storage conditions of the finished product - Other 
variation 
IB/0004 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
14/10/2017 
20/09/2018 
SmPC 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
IG/0850/G 
This was an application for a group of variations. 
12/10/2017 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 16/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
WS/1243 
This was an application for a variation following a 
28/09/2017 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
25/09/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0001 
B.I.a.2.z - Changes in the manufacturing process of 
04/08/2017 
n/a 
the AS - Other variation 
Page 17/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
